Rapid  ||| S:0 E:6 ||| JJ
tests  ||| S:6 E:12 ||| NNS
during  ||| S:12 E:19 ||| IN
respiratory  ||| S:19 E:31 ||| JJ
infection ||| S:31 E:40 ||| NN
:  ||| S:40 E:42 ||| :
an  ||| S:42 E:45 ||| DT
aid  ||| S:45 E:49 ||| NN
to  ||| S:49 E:52 ||| TO
non-prescription  ||| S:52 E:69 ||| JJ
of  ||| S:69 E:72 ||| IN
antibiotics ||| S:72 E:83 ||| NN
?  ||| S:83 E:86 ||| .
Due  ||| S:86 E:90 ||| JJ
to  ||| S:90 E:93 ||| TO
overuse ||| S:93 E:100 ||| VB
,  ||| S:100 E:102 ||| ,
we  ||| S:102 E:105 ||| PRP
are  ||| S:105 E:109 ||| VBP
about  ||| S:109 E:115 ||| RB
to  ||| S:115 E:118 ||| TO
reach  ||| S:118 E:124 ||| VB
the  ||| S:124 E:128 ||| DT
end  ||| S:128 E:132 ||| NN
of  ||| S:132 E:135 ||| IN
the  ||| S:135 E:139 ||| DT
antibiotic  ||| S:139 E:150 ||| JJ
era ||| S:150 E:153 ||| NN
.  ||| S:153 E:155 ||| .
Each  ||| S:155 E:160 ||| DT
of  ||| S:160 E:163 ||| IN
us  ||| S:163 E:166 ||| PRP
is  ||| S:166 E:169 ||| VBZ
responsible  ||| S:169 E:181 ||| JJ
to  ||| S:181 E:184 ||| TO
limit  ||| S:184 E:190 ||| VB
their  ||| S:190 E:196 ||| PRP$
usage  ||| S:196 E:202 ||| NN
to  ||| S:202 E:205 ||| TO
a  ||| S:205 E:207 ||| DT
minimum ||| S:207 E:214 ||| NN
.  ||| S:214 E:216 ||| .
Respiratory  ||| S:216 E:228 ||| JJ
infections  ||| S:228 E:239 ||| NNS
are  ||| S:239 E:243 ||| VBP
the  ||| S:243 E:247 ||| DT
first  ||| S:247 E:253 ||| JJ
cause  ||| S:253 E:259 ||| NN
of  ||| S:259 E:262 ||| IN
antibiotic  ||| S:262 E:273 ||| JJ
prescriptions ||| S:273 E:286 ||| NNS
.  ||| S:286 E:288 ||| .
The  ||| S:288 E:292 ||| DT
use  ||| S:292 E:296 ||| NN
of  ||| S:296 E:299 ||| IN
new  ||| S:299 E:303 ||| JJ
simple  ||| S:303 E:310 ||| JJ
tests  ||| S:310 E:316 ||| NNS
available  ||| S:316 E:326 ||| JJ
at  ||| S:326 E:329 ||| IN
the  ||| S:329 E:333 ||| DT
bedside  ||| S:333 E:341 ||| NN
can  ||| S:341 E:345 ||| MD
be  ||| S:345 E:348 ||| VB
very  ||| S:348 E:353 ||| RB
useful  ||| S:353 E:360 ||| JJ
in  ||| S:360 E:363 ||| IN
this  ||| S:363 E:368 ||| DT
context ||| S:368 E:375 ||| NN
.  ||| S:375 E:377 ||| .
The  ||| S:377 E:381 ||| DT
development  ||| S:381 E:393 ||| NN
of  ||| S:393 E:396 ||| IN
sophisticated  ||| S:396 E:410 ||| JJ
molecular  ||| S:410 E:420 ||| JJ
diagnostic  ||| S:420 E:431 ||| JJ
tools ||| S:431 E:436 ||| NNS
,  ||| S:436 E:438 ||| ,
such  ||| S:438 E:443 ||| JJ
as  ||| S:443 E:446 ||| IN
multiorganism  ||| S:446 E:460 ||| JJ
panels ||| S:460 E:466 ||| NNS
,  ||| S:466 E:468 ||| ,
may  ||| S:468 E:472 ||| MD
revolutionize  ||| S:472 E:486 ||| VB
our  ||| S:486 E:490 ||| PRP$
approach  ||| S:490 E:499 ||| NN
to  ||| S:499 E:502 ||| TO
respiratory  ||| S:502 E:514 ||| VB
infections ||| S:514 E:524 ||| NNS
.  ||| S:524 E:526 ||| .
The  ||| S:526 E:530 ||| DT
key  ||| S:530 E:534 ||| NN
will  ||| S:534 E:539 ||| MD
be  ||| S:539 E:542 ||| VB
to  ||| S:542 E:545 ||| TO
interpret  ||| S:545 E:555 ||| VB
the  ||| S:555 E:559 ||| DT
results  ||| S:559 E:567 ||| NNS
correctly ||| S:567 E:576 ||| RB
,  ||| S:576 E:578 ||| ,
with  ||| S:578 E:583 ||| IN
due  ||| S:583 E:587 ||| JJ
consideration  ||| S:587 E:601 ||| NN
of  ||| S:601 E:604 ||| IN
the  ||| S:604 E:608 ||| DT
statement ||| S:608 E:617 ||| NN
,  ||| S:617 E:619 ||| ,
Treat  ||| S:619 E:625 ||| NNP
patients ||| S:625 E:633 ||| NNS
,  ||| S:633 E:635 ||| ,
not  ||| S:635 E:639 ||| RB
lab  ||| S:639 E:643 ||| JJ
results ||| S:643 E:650 ||| NNS
.  ||| S:650 E:652 ||| .
